Takeda Unit, U.S. Pharma See Mixed Results From IBD Drug Trials
This article was originally published in PharmAsia News
Takeda Pharmaceutical's U.S. unit and Sucampo Pharmaceuticals report mixed results from a pair of Phase III studies on Sucampo's Amitiza (lubiprostone) to treat opioid-induced bowel dysfunction. One trial met goals; the other fell short. Amitiza has U.S. clearance to treat chronic idiopathic constipation, but the trials for the other indication indicated the companies need to continue a separate study not expected to yield data until later this year. If that study is successful, the drug makers expect to apply to the U.S. FDA for approval next year. (Click here for more
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.